What impact have selling expenses had on Novo Nordisk's profitability in 2023-2024?

Selling expenses have had a significant impact on Novo Nordisk's profitability in 2023-2024. The company's selling, general, and administrative (SG&A) expenses increased from $9.14 billion in 2023 to $9.35 billion in 2024. This rise in SG&A expenses, coupled with relatively stable revenue growth from $34.47 billion in 2023 to $40.31 billion in 2024, has put pressure on the company's net income. The net income decreased from $12.42 billion in 2023 to $14.02 billion in 2024, which may indicate that the increased selling expenses have eaten into some of the company's profit margins.

|code|Ticker|Name|Date|Total Revenue (FY)|Selling, General, and Administrative Expenses (FY)|Net Income (FY)|market_code|
|---|---|---|---|---|---|---|---|
|NVO|NVO.N|Novo Nordisk|2023|3.446622477057E10|9.14079640326E9|1.241808606471E10|169|
|NVO|NVO.N|Novo Nordisk|2024|4.030799738463E10|9.35194174917E9|1.401715560748E10|169|